跳转至内容
Merck

V6758

Sigma-Aldrich

VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human

>90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder

别名:

Vascular Endothelial Growth Factor Receptor‑2

登录查看公司和协议定价


About This Item

MDL號碼:
分類程式碼代碼:
51111800
NACRES:
NA.32

生物源

human

品質等級

重組細胞

expressed in NSO cells

化驗

>90% (SDS-PAGE)

形狀

lyophilized powder

效力

10-40 ng/mL ED50

分子量

predicted mol wt ~110 kDa

包裝

pkg of 50 μg

儲存條件

avoid repeated freeze/thaw cycles

雜質

endotoxin, tested

UniProt登錄號

儲存溫度

−20°C

基因資訊

human ... KDR(3791)

應用

VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human is a homodimeric protein contains extracellular domain of human VEGF R2 (KDR) fused to the 6x histidine tagged Fc portion of human IgG1 by the peptide (EGF). The product was used to stuyd vasculogenesis and angiogenesis and as marker for pluripotent hematopoietic stem cells.

生化/生理作用

VEGF Receptor-2 (VEGF R2) also known as Flk-1 or KDR belongs to class III subfamily of RTKs is a potent VEGF antagonist and is mainly expressed in endothelial cells. VEGF R2 can stimulate PLC-gamma pathway which in turn activate MAP kinase and subsequent strong signalling as well as can partly induces mitotic signals in NIH3T3 fibroblasts. KDR also facilitates the release of nitric oxide in endothelial cells and assist in the regulation of the vasculature.
VEGF receptors, class III receptor tyrosine kinases, have seven Ig like extracellular motifs and a tyrosine kinase intracellular domain split by a kinase insert sequence. VEGFR 1 and 2 are both expressed in an endothelial cell-specific manner.

外觀

Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline containing 2.5 mg bovine serum albumin.

分析報告

The biological activity is measured by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

B L Ziegler et al.
Science (New York, N.Y.), 285(5433), 1553-1558 (1999-09-08)
Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial
J Kroll et al.
Biochemical and biophysical research communications, 265(3), 636-639 (1999-12-22)
VEGF-A induces angiogenesis and regulates endothelial function via production and release of nitric oxide (NO), which is produced by endothelial nitric oxide synthase (eNOS). While the upregulation of eNOS expression has been shown to be mediated via VEGF receptor KDR
T Takahashi et al.
Oncogene, 14(17), 2079-2089 (1997-05-01)
KDR/Flk-1 tyrosine kinase, one of the two receptors for Vascular Endothelial Growth Factor (VEGF) has been shown to generate the major part of mitotic signals in endothelial cells, although the mechanisms are poorly understood. Here we examined the processing and
Yanelys Morera et al.
Vaccine, 35(28), 3582-3590 (2017-05-26)
CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门